Drug Profile

TYG 100

Alternative Names: APL-810; OQR 100; TYG - 100

Latest Information Update: 29 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator OncoQR
Developer Apollomics; OncoQR; TYG Oncology
Class Antineoplastics; Cancer vaccines; Immunotherapies
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer
New Molecular Entity No

Highest Development Phases

Preclinical Gastrointestinal cancer; Pancreatic cancer
Discontinued Breast cancer; Gastric cancer

Most Recent Events

29 Jul 2025 TYG 100 is still in preclinical development for Pancreatic cancer and Gastrointestinal cancer in United Kingdom (TYG Oncology pipeline, March 2016)
31 Jan 2025 Discontinued - Preclinical for Gastrointestinal cancer in USA (Parenteral)
16 Mar 2023 Discontinued - Preclinical for Gastric cancer in Austria (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com